Gearing up for an NDA filing for selective adrenergic modulator Edsivo (celiprolol) in vascular Ehlers-Danlos syndrome (vEDS), Acer Therapeutics Inc. has begun drawing attention for another candidate in the pipeline: ACER-001 in urea cycle disorder (UCD), where company-watchers are placing bets on its odds of taking market share from the only approved therapy in the space, Ravicti (glycerol phenylbutyrate), from Horizon Pharma plc.